In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Artiva Biotherapeutics, Inc., with a price target of $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar has given her Buy rating due to a combination of factors surrounding Artiva Biotherapeutics, Inc.’s promising developments in their AlloNK cell therapy. The company has made significant progress in their Phase 2a basket trial, dosing the first patient and actively enrolling more across multiple clinical sites. This trial evaluates the AlloNK therapy in combination with rituximab for various autoimmune diseases, and the initial safety data and mechanistic insights expected by the end of 2025 are highly anticipated.
Furthermore, the AlloNK therapy’s approach of using non-genetically modified cells combined with an anti-CD20 mAb distinguishes it from other therapies. This method allows for simplified manufacturing and administration, potentially offering rapid production and distribution advantages. The therapy’s success in B-NHL trials and its convenient administration could translate into similar efficacy in autoimmune trials. These factors, along with the upcoming data readouts, contribute to the positive outlook and Buy rating for Artiva’s stock.
In another report released today, Needham also maintained a Buy rating on the stock with a $18.00 price target.